INDICATION:
GEMCOVAC-OM is indicated as a booster for active immunization for the prevention of COVID-19 in individuals 18 years of age and older who have received either COVAXIN or COVISHIELD as primary vaccination.
GEMCOVAC-OM should be administered in single dose in individuals aged ≥ 18 years administered at least 4 months after completion of primary vaccination with either COVISHIELD or COVAXIN. A volume of 0.1 mL should be administered
intradermally using a Needle- free Tropis Injection system (PharmaJet, Colorado, USA)
Special Populations
Elderly population: No dose adjustment is required for the elderly population.
Pediatric population: The safety and efficacy of GEMCOVAC-OM has not been
established in children and adolescents <18 years of age.
Contraindications
Hypersensitivity to any constituents of GEMCOVAC-OM.
Individuals below 18 years of age.
Special warnings and precautions for use
GEMCOVAC-OM should not be administered intravenously, intramuscularly or subcutaneously.
Your email address will not be published. Required fields are marked *